Year: 2026
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
Abstract: BACKGROUND: Adaptive behavior requires flexibly balancing approach and avoidance in risky or threatening environments, a flexibility disrupted in depression and other disorders marked by excessive avoidance. Benzodiazepines such as lorazepam broadly dampen neural excitability and synaptic plasticity, whereas ketamine may enhance both. We therefore asked whether ketamine promotes more strategic and efficient motivational behavior. METHODS: In this completed randomized crossover study, 34 healthy participants with no lifetime neurological or psychiatric disorders and no regular medication use were assessed at the University Medical Center Freiburg (DRKS00025471). Participants completed three visits separated by seven days: a control visit without medication, followed by intranasal ketamine (50 mg) and oral lorazepam (1 mg) in randomized, counterbalanced order. Threat probability and loss magnitude were varied independently in a dynamic approach-avoidance conflict task conducted after ketamine's acute dissociative phase. Reported behavioral outcomes were net token gain, approach behavior, and approach and withdrawal latencies. Behavioral assessors were blinded to condition; participants and physicians were not. Mixed-effects models were used. RESULTS: All 34 randomized participants completed each condition and were analyzed. Ketamine yielded 57% higher token gains than control (β = 0.09, 95% confidence interval 0.05 to 0.13; p < 0.001) and 33% higher gains than lorazepam (β = 0.05, 0.01 to 0.09; p = 0.009). Behavior following ketamine was more strongly guided by outcome value than threat probability and showed faster approach and withdrawal responses. Lorazepam produced a less selective increase in approach behavior. No unexpected adverse events occurred. CONCLUSIONS: In healthy participants, ketamine was associated with more efficient and value-sensitive approach-avoidance behavior than control and lorazepam.
Source: Communications Medicine
Language: English
Subfield: Pharmacology (medical)
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,690
Award: G2755775432
OpenAlex ID: W7237017152
